ReviewCureus2025
Emerging Novel Therapies for the Treatment of Psoriasis: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis in mice: effects alone and in combination with methotrexate.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic autoimmune and autoinflammatory disorder defined by abnormal skin cell turnover and inflammation, resulting in the formation of plaques on the skin. Although biologic therapies targeting interleukin (IL)-17 and IL-23 have significantly improved the treatment landscape for moderate-to-severe psoriasis, they are not effective for all patients. This highlights the need for additional therapeutic strategies. In recent years, exploring novel treatment avenues such as targeting IL-21, small nucleolar RNA (snoRNA) Snora73, the gut microbiome, and natural remedies have shown increasing promise in managing psoriasis. Interleukin-21 is a cytokine that plays a critical role in the differentiation and function of Th17 cells, which are central to the pathogenesis of psoriasis. Recent studies have demonstrated that neutralizing IL-21 with specific antibodies can help restore immune homeostasis, reducing disease severity and improving patient outcomes. Targeting IL-21 may be particularly beneficial for patients resistant to conventional therapies like IL-17 and IL-23 inhibitors. In addition to IL-21, snoRNA Snora73 has emerged as a novel target for psoriasis treatment. Snora73 regulates cell proliferation by interacting with miR-3074-5p and pre-B-cell leukemia homeobox 1 (PBX1), promoting abnormal cell turnover in psoriasis. The gut microbiome is increasingly recognized for its role in autoimmune diseases, including psoriasis. Imbalances in the microbiome have been linked to disease exacerbation, triggering systemic inflammation and altering immune responses. Moreover, various natural treatments have gained attention for their anti-inflammatory properties. These natural therapies could serve as adjuncts to existing treatments, offering a complementary approach that minimizes side effects while improving patient outcomes. Targeting IL-21, Snora73, and the gut microbiome, as well as utilizing natural treatments, may provide new opportunities for more effective, personalized management of psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.